Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sabrina McDonnell"'
Autor:
Michael Wagner, Lee Cranmer, Seth Pollack, Qianchuan He, Yuzheng Zhang, Elizabeth Loggers, Sabrina McDonnell, Shannon Maxwell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/8d2a90a134bf494fa5b4e81dda8ac519
Autor:
Seth M. Pollack, Robin L. Jones, Qianchuan He, Kimberly S. Smythe, Lauri Aicher, Pedro Hermida de Viveiros, Roxanne Moore, Rylee Johnson, Shannon Maxwell, Sabrina McDonnell, Graeme Black, Elizabeth T. Loggers, Lee D. Cranmer, Yuzheng Zhang, Michael J. Wagner
Purpose:Leiomyosarcoma and liposarcoma frequently express PD-L1 but are generally resistant to PD-1/PD-L1 inhibition (immune checkpoint inhibitor). Trabectedin is FDA approved for leiomyosarcoma and liposarcoma. This study aimed to evaluate the safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b61711fc06b28a771520f1998ca3c692
https://doi.org/10.1158/1078-0432.c.6532298.v1
https://doi.org/10.1158/1078-0432.c.6532298.v1
Autor:
Seth M. Pollack, Robin L. Jones, Qianchuan He, Kimberly S. Smythe, Lauri Aicher, Pedro Hermida de Viveiros, Roxanne Moore, Rylee Johnson, Shannon Maxwell, Sabrina McDonnell, Graeme Black, Elizabeth T. Loggers, Lee D. Cranmer, Yuzheng Zhang, Michael J. Wagner
Supplementary Data from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ce444ab474c6717d309fd74bef312f0
https://doi.org/10.1158/1078-0432.22486367.v1
https://doi.org/10.1158/1078-0432.22486367.v1
Autor:
Seth M. Pollack, Robin L. Jones, Qianchuan He, Kimberly S. Smythe, Lauri Aicher, Pedro Hermida de Viveiros, Roxanne Moore, Rylee Johnson, Shannon Maxwell, Sabrina McDonnell, Graeme Black, Elizabeth T. Loggers, Lee D. Cranmer, Yuzheng Zhang, Michael J. Wagner
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0825a3bc36ed0f2e705ebadbebfa3543
https://doi.org/10.1158/1078-0432.22486352.v1
https://doi.org/10.1158/1078-0432.22486352.v1
Autor:
Michael J. Wagner, Yuzheng Zhang, Lee D. Cranmer, Elizabeth T. Loggers, Graeme Black, Sabrina McDonnell, Shannon Maxwell, Rylee Johnson, Roxanne Moore, Pedro Hermida de Viveiros, Lauri Aicher, Kimberly S. Smythe, Qianchuan He, Robin L. Jones, Seth M. Pollack
Publikováno v:
Clin Cancer Res
Purpose: Leiomyosarcoma and liposarcoma frequently express PD-L1 but are generally resistant to PD-1/PD-L1 inhibition (immune checkpoint inhibitor). Trabectedin is FDA approved for leiomyosarcoma and liposarcoma. This study aimed to evaluate the safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::070d02718eba04790668a6bb1a90b2b2
https://pubmed.ncbi.nlm.nih.gov/35349638
https://pubmed.ncbi.nlm.nih.gov/35349638
Autor:
Seth M. Pollack, Qianchuan He, Yuzheng Zhang, Michael R. Wagner, Shannon Maxwell, Sabrina McDonnell, Lee D. Cranmer, Elizabeth T. Loggers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Leiomyosarcoma (LMS) and liposarcoma (LPS) are soft tissue sarcoma subtypes that frequently express PD-L1 and are infiltrated with T cells. They are generally resistant to PD-1/PD-L1 inhibition, possibly due to infiltration with high level
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71166f336802fec611b16e9941194e90
https://doaj.org/article/8d2a90a134bf494fa5b4e81dda8ac519
https://doaj.org/article/8d2a90a134bf494fa5b4e81dda8ac519
Autor:
Lee D. Cranmer, Mary W. Redman, Roxanne Moore, Elizabeth T. Loggers, Michael J. Wagner, Brett Schroeder, Rylee Johnson, Seth M. Pollack, Graeme Black, Sabrina McDonnell, Jeffrey Gregory, Shihong Zhang, Kelsey Baker, Vanessa C. Copeland, Robin L. Jones, Kathryn Trieselmann
Publikováno v:
JAMA Oncol
Importance Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in patients with soft-tissue sarcoma over doxorubicin m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b8c52430d37a58dc54be478c2a17e4
https://pubmed.ncbi.nlm.nih.gov/33507225
https://pubmed.ncbi.nlm.nih.gov/33507225
Autor:
Michael J. Wagner, Sabrina McDonnell, Roxanne Moore, Lee D. Cranmer, Mary W. Redman, Elizabeth T. Loggers, Kelsey Baker, Robin L. Jones, Michael Shahnazari, Seth M. Pollack, Jeffrey Gregory, Vanessa C. Copeland, Steven M. Townson, Kathryn J. Hammer, Rylee Johnson
Publikováno v:
Journal of Clinical Oncology. 37:11009-11009
11009 Background: Patients with advanced soft tissue sarcomas (STS) treated with single agent Dox have a median progression-free survival (PFS) of 4.6 months (mo) and response rate (RR) of 14%. Dox sensitizes tumors to Pem through calreticulin releas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e51535042453890f5ddc845af8378e0a
https://doi.org/10.1200/jco.2019.37.15_suppl.11009
https://doi.org/10.1200/jco.2019.37.15_suppl.11009